-- Earnings Flash (CTMX) CYTOMX THERAPEUTICS Posts Q2 Revenue $18.2M
4:19PM ET 8/04/2022 MT Newswires...
Quotes Snapshot > CTMX
CytomX Therapeutics Inc CTMX:NASDAQ
Last Price$1.72Cboe Real-Time Last Sale as of 11:08AM ET 8/15/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.05(2.99%)
Bid (Size)$1.71 (2,000)
Ask (Size)$1.72 (569)
Day Low / High$1.67 - 1.74
Volume335.5 K
Read more news Recent News
CytomX Therapeutics to Cut Workforce by 40%, Extends Cash Runway into 2025
4:21PM ET 7/13/2022 MT NewswiresCytomX Therapeutics (CTMX) said Wednesday it is restructuring its business to prioritize internal investments in its emerging pre-clinical and early...
Cowen Downgrades CytomX Therapeutics to Market Perform From Outperform
8:51AM ET 7/11/2022 MT NewswiresCytomX Therapeutics (CTMX) has an average rating of outperform and price targets ranging from $1.50 to $8, according to analysts polled by Capital IQ. (MT...
HC Wainwright Downgrades CytomX Therapeutics to Neutral From Buy
6:14AM ET 7/11/2022 MT NewswiresCytomX Therapeutics (CTMX) has an average rating of outperform and price targets ranging from $1.50 to $11, according to analysts polled by Capital IQ. (MT...
View all Commentary and Analysis
CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q2 2022 Results - Earnings Call Transcript
8:40PM ET 8/05/2022 Seeking AlphaCytomX Therapeutics (CTMX) Investor Presentation - Slideshow
3:36PM ET 6/09/2022 Seeking AlphaCytomX Therapeutics' (CTMX) CEO Sean McCarthy on Q1 2022 Results - Earnings Call Transcript
3:17PM ET 5/07/2022 Seeking AlphaCytomX Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation
2:30PM ET 3/04/2022 Seeking AlphaCompany Profile
Business DescriptionCytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA. View company web site for more details
| Address | 151 Oyster Point Boulevard South San Francisco, California 94080-1913 |
| Phone | +1.605.515.3185 |
| Number of Employees | 137 |
| Recent SEC Filing | 08/12/2022 4 |
| Chairman, President & Chief Executive Officer | Sean A. McCarthy |
| Chief Financial Officer & Senior Vice President | Carlos E. Campoy |
| Senior Vice President & Head-Research | Marcia P. Belvin |
| Chief Medical Officer & Senior Vice President | Alison L. Hannah |
Company Highlights
| Price Open | $1.68 |
| Previous Close | $1.67 |
| 52 Week Range | $1.19 - 7.53 |
| Market Capitalization | $113.4 M |
| Shares Outstanding | 66.0 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 11/03/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$1.48 |
| Beta vs. S&P 500 | N/A |
| Revenue | $59.5 M |
| Net Profit Margin | -133.42% |
| Return on Equity | -121.88% |
Analyst Ratings as of 07/08/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |